CTRI/2018/07/014730Recruiting未知
Determination of Microsatellite Instability Status from Cell-free DNA of Patients with Endometrial, Colon, Stomach and Rectal Cancers.
exent Bio Inc0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or older
- •1 Able to understand and grant informed consent
- •2 Able to have their blood drawn at enrolment
- •3 Registration and blood draw should be before surgery for patients with surgically resectable disease or before initiation of active therapy with non resectable disease
- •4 Prior therapy is allowed as long as there is locally advanced or metastatic measurable and/or non measurable but evaluable disease progression orrecurrence since last treatment
- •5 Availability of tissue sections or tumour containing tissue block either from a previously obtained or planned surgery.
- •6 Biopsy confirmed adenocarcinoma of the colon or rectum, endometrial cancers, or adenocarcinoma of the stomach including gastroesophageal adenocarcinomas
Exclusion Criteria
- •Unable to grant informed consent or comply with all study procedures
- •Only non measurable or non evaluable disease at the time of blood collection
- •Non-malignant tumors
Investigators
Similar Trials
Recruiting
Not Applicable
Research study for microsatellite instability in malignancy in hepato-biliary-pancreatic field (KHBO 1903-1-2)Malignancy in hepato-biliary-pancreatic fieldJPRN-UMIN000045249Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University400
Completed
Not Applicable
Synchronous neoplasm of stomach and coloDiseases of the digestive systemKCT0000948Konkuk University Medical Center598
Active, not recruiting
Unknown
Whether high-risk features (HRFs) on the recurrence or microsatellite instability (MSI) status are predictive markers for adjuvant chemotherapy (ACT) in patients with stage II colon cancer is uncertain. This study aimed to examine the impact of HRFs and MSI on the prediction of the benefits of ACT in patients with stage II colon cancer. This multi-center retrospective study included 1801 patients with resected stage II colon cancer diagnosed at 17 university-affiliated hospitals between January 2010 and December 2017.NeoplasmsKCT0009579Keimyung University Dongsan Hospital1,300
Unknown
Not Applicable
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid TumorsSolid TumorNCT03596593Peking University8,000
Not yet recruiting
Unknown
Prevalence of common hereditary cancer syndrome- Lynch syndrome- across different tumour types in IndiaCTRI/2024/03/063560Foundation for Research in Genetics and Endocrinology